KEW Announces 2016 ASCO Abstract

–Data Show CANCERPLEX® Sequencing Analysis Leads to Appropriate and Successful Targeted Treatment of Lung Cancers as Supported by the Literature–

CAMBRIDGE, Massachusetts (June 3, 2016) – KEW, Inc. announced today that the company has an abstract published in conjunction with the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in the tumor biology, molecular diagnostics and imaging category. Analysis of 125 non-small cell lung cancer adenocarcinoma patient tumors using CANCERPLEX FP next-generation sequencing of over 400 cancer genes identified key mutations that predict response to FDA-approved therapies, including negative predictors of response, pathway inhibition and mutation burden, which predicts a patient’s likely positive response to immune-checkpoint inhibition therapies. The study concluded that tumor specific sequencing analysis using CANCERPLEX FP leads to appropriate and successful targeted treatment of lung cancers as supported by the literature.

The full abstract is available in the Journal of Clinical Oncology:
Jiang J, Eifert C, Lyle S, Protopopov A, Sun R, Pantazi A, Heyer J, Russell M. Clinical next generation sequencing in lung cancer: Beyond personalized medicine. J Clin Oncol 34, 2016 (suppl; abstr e23128).

About KEW, Inc.

KEW, Inc. provides comprehensive genomic testing services that enable oncologists to make evidence-driven personalized treatment decisions for cancer patients. Based out of Cambridge, MA, KEW was founded by pioneers of the precision medicine industry, including key contributors to the Human Genome and The Cancer Genome Atlas projects. The CANCERPLEX® suite of products offers flexible panel sizes, the largest of which sequences 400+ cancer genes in solid tumors that are the most relevant to oncology patient care. Specialized panels offer the option to test based on the site of a patient’s tumor or to limit results to FDA-approved therapies. CANCERPLEX not only makes personalized medicine more accessible, it delivers the promise of precision medicine for all. For more news and information, please visit

KEW, Inc.
Mary Burt


< News & Events